LivaNova PLC (LIVN)
Fair ValueFundamental
64
मूल्य
$75.41
मार्केट कैप
$4.21B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 सितंबर 2026 with claude-haiku-4-5 — shared with all users
Through its Maquet Cardiopulmonary unit, Getinge sells the heart-lung machines, oxygenators and ECMO circuits that LivaNova's Cardiopulmonary segment sells to the same hospital perfusion and cardiac-surgery departments worldwide.
Terumo's cardiovascular business supplies oxygenators, perfusion systems and disposables for open-heart surgery, overlapping directly with LivaNova's largest revenue line and competing for the same hospital tenders.
Medtronic competes on both of LivaNova's fronts — cardiopulmonary bypass equipment and disposables for cardiac surgery, and implantable neurostimulators used in drug-resistant epilepsy and difficult-to-treat neurological conditions.
NeuroPace's RNS responsive neurostimulation system targets the same drug-resistant focal epilepsy patients, and the same implanting epilepsy centres, that LivaNova's VNS Therapy depends on.
Haemonetics competes in the surgical blood-management products used in the same cardiac operating room, where LivaNova sells autotransfusion and blood-handling systems alongside its bypass equipment.
This privately held UK manufacturer sells perfusion monitoring and extracorporeal circuit systems to the same cardiac surgery units, and is named by LivaNova itself among its principal competitors.
बैलेंस शीट और तरलता
राजस्व
$1.47B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$189M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$173M
कुल इक्विटी
$1.20B
कुल देनदारियाँ
$1.41B
Current Ratio
1.45
Interest Coverage
5.43
Debt/EBITDA
1.34
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$67.01
वर्तमान मूल्य
$75.41
Margin of Safety
-12.5%
Fair Value सीमा
$48.94 - $85.07
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
22.57
ROE
-20.2%
P/B Ratio
3.18
P/FCF
28.42
Gross Margin
68.1%
ROIC
7.7%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
7.7%
WACC
9.7%
ROIC − WACC
-2.0 pp
ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।
Fundamental विश्लेषण मानदंड
पास (18)
- Price CAGR 5.55%
- ROIC 7.7%
- Gross Margin 68.1%
- P/FCF 28.42
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.4%
- Revenue Growth 5Y 8.2%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 10.3%
- Earnings Quality (OCF/NI) 1.32
- Share Dilution -0.0%
- Net Margin Trend 12.8% vs -16.1%
फेल (7)
- EPS shows upward trend
- P/B Ratio 3.18
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Piotroski F-Score 4/9
अनुपलब्ध (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
इस कंपनी के लिए कोई संस्थागत घोषणा उपलब्ध नहीं है।
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Vladimir A. Makatsaria | CEO & Director | 52 |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer | 55 |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer | 54 |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer | 50 |
| Ms. Lindsey Little | VP & Chief Accounting Officer | - |
| Briana Gotlin | Vice President of Investor Relations | - |
| Ms. Anne M. Liddy | Chief Legal Officer | 49 |
| Deanna Wilke | Vice President of Corporate Communications | - |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer | - |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 69 |
Audit जोखिम
9
बोर्ड जोखिम
3
मुआवजा जोखिम
2
शेयरधारक अधिकार जोखिम
2
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-25
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-05
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-08-05
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for LIVN, sourced from Markets Gazette.
- 2/25/2026NEUTRALLivaNova (LIVN) Q4 2025 Earnings Call Transcript
The transcript of LivaNova PLC's Q4 2025 earnings conference call is now available, providing investors with a critical opportunity to delve into the company's financial performance and future outlook. While the specific content has not been disclosed, analysts and shareholders will be scrutinizing management's statements regarding revenues, profit margins, product pipeline, and guidance for the current fiscal year. This data is essential for assessing LivaNova's operational health and anticipating potential stock movements, thereby influencing both short-term and long-term investment strategies.
via Markets Gazette